Celltrace Violet News Today

Science for just $15 USD. Short circuiting solid tumors Two major hurdles in chimeric antigen receptor (CAR) T cell therapy for solid tumors are ensuring specificity to tumor cells without affecting healthy cells and avoiding tumor escape due to antigen loss. To address these challenges, Hyrenius-Wittsten et al. and Choe et al. developed synthetic Notch (synNotch)–CAR T cells targeting solid tumor antigens and used them to treat mouse models of mesothelioma, ovarian cancer, and glioblastoma...

Expert Insight: CAR T: Dual-targeted cell therapy to prevent relapsed multiple myeloma: Your questions answered Watch this on-demand webinar to find out how targeting B-cell maturation antigen and GPRC5D simultaneously could help to prevent tumor cell escape 15 Dec 2020 Carlos Fernández de Larrea, University of Barcelona and Rogier M. Reijmers, LUMICKS There have been significant advances in the treatment of relapsed multiple myeloma over the past decade, which in turn has resulted in an incr...